A new pancreatic cancer drug has produced a result that deserves attention.

Daraxonrasib is a once-daily pill being tested for people with metastatic pancreatic cancer. Metastatic means the cancer has spread beyond the pancreas.

In the phase 3 RASolute 302 trial, the drug was tested in people whose cancer had already progressed after chemotherapy.

The trial enrolled 500 patients across North America, Europe and Asia. Patients received either daraxonrasib or standard second-line chemotherapy.

The survival difference was large.

People given daraxonrasib had a median overall survival of 13.2 months. People given chemotherapy had a median overall survival of 6.7 months.

That does not mean every person lived that long. Median means the middle point in the group. Half lived longer and half lived for less time.

But in pancreatic cancer, where survival is often short and treatment options can be limited, that difference matters.

Progression-free survival also improved. That means the time before the cancer grew again or the patient died. It was 7.2 months with daraxonrasib and 3.6 months with chemotherapy.

This is a serious result.

It is not a cure.

It is not routine NHS treatment.

It does not mean every pancreatic cancer patient can get the drug now.

Why this drug matters

Most pancreatic cancers are driven by faults in the RAS family of genes, especially KRAS.

These faults help cancer cells keep receiving growth signals when they should not. For years, RAS was one of the hardest cancer targets to block with drugs.

Daraxonrasib is designed to interfere with that signalling. It is taken by mouth, not given by intravenous infusion.

That is why the trial has attracted attention. It is not only another chemotherapy comparison. It is a targeted drug showing a survival gain in a disease where progress has been slow.

What happens next

The next stage is approval and access.

In the United States, the FDA has allowed an expanded access treatment protocol for eligible patients with previously treated metastatic pancreatic ductal adenocarcinoma.

That is not the same as full approval.

Expanded access means some patients may be able to receive an investigational drug before approval. The FDA notice says requests must be submitted by licensed US physicians on behalf of eligible patients.

So the route is doctor-led. It is not a public prescription route and it is not a general green light.

In the UK, the position is different.

Daraxonrasib is not yet routine NHS treatment.

There is a UK-listed daraxonrasib study recruiting in Birmingham and London, but that study is for resected pancreatic ductal adenocarcinoma. That is not the same patient group as the headline phase 3 trial, which involved previously treated metastatic disease.

Routine NHS access would need the usual access chain: regulatory approval, assessment for NHS use, funding, and delivery through the health service.

The MHRA and NICE now have an aligned pathway intended to get some new medicines to patients sooner by bringing licensing and value decisions closer together. But that does not mean every drug enters that pathway, and it does not mean daraxonrasib is already available.

The timeline

13 April 2026: Revolution Medicines announced positive phase 3 results.

1 May 2026: The FDA allowed a US expanded access treatment protocol for eligible patients.

31 May 2026: The full result was presented at the American Society of Clinical Oncology meeting and reported by Dana-Farber.

1 June 2026: The drug remains investigational. It is not routine NHS treatment.

The next steps are regulatory submission, review, and decisions about public access.

The careful way to read this

There are two bad ways to report this story.

The first is to write it as miracle medicine. That would be false.

The second is to flatten it into another cautious research story. That would miss the scale of the result.

The better reading is plain.

A drug has nearly doubled median survival in a large trial for previously treated metastatic pancreatic cancer. That is real hope for a disease where people often have very little time.

But hope is not access.

A trial result has arrived before the access route.

That is the gap now.

Daraxonrasib may become a major pancreatic cancer treatment. But on 1 June 2026, UK patients cannot assume they can get it through the NHS.

The next stage is approval, funding and delivery.